Harbin Pharmaceutical Group Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.1yrs
Gemiddelde ambtstermijn bestuur	2.4yrs

Recente managementupdates

Recent updates

CEO

Harbin Pharmaceutical Group heeft geen CEO, of we hebben geen gegevens over hen.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Bo Jiang	CFO & VP	3.8yrs	CN¥1.31m	geen gegevens
Xiaodong Meng	VP & Secretary	less than a year	CN¥1.31m	0.013% CN¥ 1.2m
Haitao Jiang	Vice President	2.6yrs	CN¥691.90k	0.0019% CN¥ 177.0k
Jicheng Xia	Vice President	2.1yrs	CN¥467.60k	0.0032% CN¥ 294.7k
Bangdong Li	Vice President	2.1yrs	CN¥578.60k	0.0016% CN¥ 147.4k

2.1yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 600664 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Aidong Lou	Independent Director	3.8yrs	CN¥150.00k	geen gegevens
Weihong Lu	Independent Director	3.8yrs	CN¥150.00k	geen gegevens
Zhaohua Li	Independent Director	3.8yrs	CN¥150.00k	geen gegevens
Ying Lei	Independent Director	less than a year	geen gegevens	geen gegevens
Xiaoping Hu	Chairman	3.8yrs	geen gegevens	geen gegevens
Shiwei Yin	Director	2.8yrs	geen gegevens	geen gegevens
Zhifeng Sun	Director	2.4yrs	geen gegevens	geen gegevens
Fangju Qiu	Employee Supervisor	less than a year	geen gegevens	0.000080% CN¥ 7.4k
Liu Mo	Director	less than a year	geen gegevens	geen gegevens
Cheng Peng	Supervisor	less than a year	geen gegevens	geen gegevens
Wenguang Peng	Chairman of the Supervisory Board	less than a year	geen gegevens	geen gegevens

2.4yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 600664 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.4 jaar), wat duidt op een nieuw bestuur.

Harbin Pharmaceutical Group Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

High number of new and inexperienced directors

Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 07, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.061 (vs CN¥0.053 in 3Q 2023)

Investor sentiment improves as stock rises 22%

Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Second quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.022 in 2Q 2023)

High number of new and inexperienced directors

Investor sentiment improves as stock rises 18%

Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.19 in FY 2022)

Harbin Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

New minor risk - Financial data availability

Investor sentiment deteriorates as stock falls 18%

Harbin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 11, 2024

Third quarter 2023 earnings released: EPS: CN¥0.053 (vs CN¥0.012 in 3Q 2022)

Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.15 in FY 2021)

Full year 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.15 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.012 (vs CN¥0.06 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.009 (vs CN¥0.12 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.03 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.15 (vs CN¥0.43 loss in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.014 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.06 loss in 2Q 2020)

Ecmoho Limited and Harbin Pharmaceutical Group Announce Joint Launch of New Iron Supplement Product

First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.07 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.43 loss per share (vs CN¥0.02 profit in FY 2019)

Harbin Pharmaceutical Group Co., Ltd.(XSSC:600664) dropped from S&P Global BMI Index

New 90-day low: CN¥2.84

New 90-day low: CN¥3.09

New 90-day low: CN¥3.22

Third quarter earnings released

New 90-day low: CN¥3.33

Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

First half earnings released

Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020

CEO

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd